Skip to main content
Equibles
OLMA logo

OLMA · Olema Pharmaceuticals, Inc.

Track OLMA — free

Use OLMA with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$10.73 -0.10 (-0.92%)
Russell 2000 member Rebalance outlook locked
Going-concern doubt — flagged Aug 10, 2026

Substantial doubt about the company's ability to continue as a going concern.

“In addition, our condensed consolidated financial statements for the six months ended June 30, 2026 and 2025 included elsewhere in this Quarterly Report have been prepared assuming we will continue as a going concern. However, we have incurred losses and negative cash flows from operations. As a development stage company, we expect to incur significant and increasing losses until regulatory approval is granted for palazestrant or OP-3136. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our ability to continue as a going concern over the long term.”
View the 10-Q filed Aug 10, 2026
Market Cap
$923.97M
Shares
87.50M

OLMA metrics

51 of 114 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$10.83
Market cap
$923.97M

Price action

19 metrics
Price change (1W)
-0.2%
Price change (30D)
-7.9%
Price change (3M)
+3.0%
Price change (6M)
-55.5%
Price change (YTD)
-56.7%
Price change (1Y)
+67.4%
Trailing year
Price change (5Y)
-63.3%
52-week high
$35.83
52-week low
$6.29
Change from 52-week high
-69.8%
Change from 52-week low
+72.2%
Annualized volatility
158.6%
Beta
0.3
RSI (14D)
48.2
Price vs SMA 50
-5.2%
Price vs SMA 200
-38.9%
Avg volume (3M)
1.34M
Relative volume
0.7
Average dollar volume
$14.79M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
87.50M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
2.1
reciprocal yield 46.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-22.1%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-26

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$221.13M
Net income (TTM)
−$204.57M
Trailing 12 months
Diluted EPS (TTM)
$-2.13
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$8.60

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+22.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-47.5%
Return on assets
-42.0%
Debt / equity
—
Current ratio
8.9
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.9
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$461.07M
Latest balance sheet
Cash & equivalents
$48.60M
Total assets
$486.58M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$164.74M
Capital expenditures (TTM)
—
R&D (TTM)
$190.19M
SG&A (TTM)
—
Stock compensation (TTM)
$31.57M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
186
13F filer change QoQ
-16
Institutional ownership
117.5%

Short interest

3 metrics
Short interest
18.1%
Latest settlement · 14.3 days to cover
Days to cover
14.3d
Short-squeeze score
65 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$291,162
Insider-sentiment score
43 / 100

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1750284 CUSIP 68062P106 13F (30d) 163 filings 161 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)